Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Kilmer S McCully Added: 3 years ago
Discovery of the Homocysteine Theory of Arteriosclerosis The American biochemist Vincent DuVigneaud discovered a new amino acid in 1932 by treating methionine with sulfuric acid. The structure of this amino acid is similar to cysteine, except for one extra carbon atom, hence the name homocysteine. Subsequent investigation established the role of homocysteine as an intermediate in sulfur amino… View more

Prevention & Chronic Conditions
Author(s): Kilmer S McCully Added: 3 years ago
Discovery of the Homocysteine Theory of Arteriosclerosis The American biochemist Vincent DuVigneaud discovered a new amino acid in 1932 by treating methionine with sulfuric acid. The structure of this amino acid is similar to cysteine, except for one extra carbon atom, hence the name homocysteine. Subsequent investigation established the role of homocysteine as an intermediate in sulfur amino… View more

Prevention & Chronic Conditions
Author(s): Wolfgang Herrmann , Rima Obeid Added: 3 years ago
Homocysteine (Hcy) is a non-essential, non-protein-forming amino acid that originates in methionine via a transmethylation reaction. Hcy is catabolized into methionine or cysteine. Methionine synthase and its co-factor, methylcobalamin, enhance the methylation of Hcy into methionine, where 5-methyl tetrahydrofolate donates its methyl group to Hcy. The trans-sulfuration pathway of Hcy catabolism… View more

Prevention & Chronic Conditions
EHRA 24: A Substudy of NOAH-AFNET 6
Author(s): Julius Nikorowitsch Added: 3 days ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from… View more

Electrophysiology & Arrhythmia
ESC 23: MULTISTARS AMI Trial
Author(s): Linda Joosten Added: 7 months ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial. FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists … View more

Anticoagulation

Demographic
Author(s): Michela Faggioni , Michael C Gibson , Roxana Mehran Added: 3 years ago
The use of non-vitamin K antagonist oral anticoagulants (NVKA) has revolutionized the antithrombotic treatment of patients with atrial fibrillation (AF), finally freeing them of the inconvenience and expense of international normalized ratio measurements. However, add to the equation the presence of coronary artery disease requiring percutaneous coronary intervention (PCI) with stent placement… View more

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
AHA 23: KABUKI: DOAC in Pts with CTEPH
Author(s): Kazuya Hosokawa , Abe Kotaro Added: 5 months ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3… View more

Prevention & Chronic Conditions
CardioNerds @AHA23: ARIES HM3: Avoidance of Aspirin with LVAD Devices
Author(s): Mandeep Mehra , Christian Inchaustegui Added: 4 months ago
AHA 2023 - Investigator, Dr Mandeep Mehra (Brigham and Women's Hospital, US) is interviewed by Dr Christian Inchaustegui (Oregon Health & Science University, US), CardioNerds Ambassador, on the findings of the ARIES HM3 trial (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES… View more

Heart Failure

Electrophysiology & Arrhythmia
AHA 23 Late-Breaker Discussion: The ARIES HM3 Clinical Trial
Author(s): Harriette Van Spall , Mandeep Mehra Added: 5 months ago
AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were… View more

Heart Failure

Electrophysiology & Arrhythmia
Ileana L Piña
Dr Ileana L Pina is Professor at the Department of Medicine (Cardiology) and Professor in the Department of Epidemiology and Population Health at Montefiore Einstein Center for Heart and Vascular Care, US. Dr Piña has a particular research and clinical interest in rehabilitation of heart disease in patients with heart failure. She completed a NHLBI HF ACTION trial and is in the process of… View more